WO2008140353A1 - Средство, обладающее свойством формировать клеточный иммунитет против мусоbасtеrium tubеrсulоsis h37 rv, способ получения его (варианты), рекомбинантный штамм и средство для диагностики туберкулеза - Google Patents
Средство, обладающее свойством формировать клеточный иммунитет против мусоbасtеrium tubеrсulоsis h37 rv, способ получения его (варианты), рекомбинантный штамм и средство для диагностики туберкулеза Download PDFInfo
- Publication number
- WO2008140353A1 WO2008140353A1 PCT/RU2008/000270 RU2008000270W WO2008140353A1 WO 2008140353 A1 WO2008140353 A1 WO 2008140353A1 RU 2008000270 W RU2008000270 W RU 2008000270W WO 2008140353 A1 WO2008140353 A1 WO 2008140353A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tuberculosis
- antigen
- strain
- complex
- species
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Definitions
- the invention relates to the field of biopharmacology, preparative biochemistry, medicine, and for the creation of funds based on the tuberculosis complex produced by the microorganism, which can be used in the treatment and diagnosis of tuberculosis.
- tubersulosis H37 Ra and transferring fragments of the chromosomal DNA of the causative agent of tuberculosis to the recipient bacteria E. coli XL-Blue. It has been shown that from a specific fragment of the chromosomal DNA of M. tubersulsis H37 Ra, which
- SUBSTITUTE SHEET (RULE 26) consists of 1535 base pairs and is part of the plasmid vector pZx7, the synthesis of tuberculosis protein with an approximate mass of 52.0 kDa is possible.
- This protein is localized on the external membrane of E. coli XL 1-Blue; it gives the recombinant strain the ability to penetrate into HeLa eukaryotic cells and multiply in them, which is typical for pathogenic mycobacteria.
- the authors do not indicate that this protein is individual (species-specific) and can be used to diagnose the causative agent of tuberculosis.
- the amino acid sequence of the studied protein has homology both with pathogenic microorganisms (List KochrioposutShis, Shigella, Jer ⁇ pi réelle ps Canalud Desid
- ⁇ -adaptin (1) a number of human proteins, for example, ⁇ -adaptin (1).
- the secreted MPT63 protein having a molecular weight of 18.0 kDa, was isolated and characterized from the filtrates of the culture of M. tubersulosis. Analysis of the nucleotide sequence of the mp + 63 gene showed that it has an open reading frame encoding a protein of 159 amino acids and consisting of 29 amino acids of the signal peptide and 130 amino acids of the mature MPT63 protein. Recombinant MPT63 protein from E. coli cells and purified from M. tuberculosis culture filtrates were indistinguishable in serological reactions and had a strong effect on the humoral immunity of guinea pigs infected with a virulent strain of M. tubulixis. It was supposed to use this protein as a specific reagent for the diagnosis of skin testing for tuberculosis, but so far this protein and the protein complex with the signal peptide have not been widely used (2).
- SUBSTITUTE SHEET (RULE 26) The description and characterization of the 4 major secreted extracellular proteins of M. tuberculosis isolated from non-pathogenic rapidly growing mycobacteria, which have enzymatic activity and are also present in pathogenic strains, is also known. These proteins are supposed to be used for the construction of biological vaccines, since they induce protective immunity, but so far they have not received recognition (3).
- the objective of the invention is to obtain, by genetic engineering and microbiological methods, a recombinant strain 2-9XL Acipetobaster johpsopii, a producer of a specific tuberculosis complex M. tuberculosis H37 Rv, which can be the basis of a biological vaccine against the causative agent of tuberculosis and a diagnosticum for identifying patients with various tuberculosis diseases and in various stages of the disease.
- a recombinant strain of 2-9XL Asipetobaster joppsopii obtained by genetic engineering method with subsequent selection of a SUBSTITUTE SHEET (RULE 26) was proposed microbiological method, which is a producer of a species-specific glycoprotein tuberculosis complex (TB antigen), which is localized on the outer membrane and in the capsular substance of the bacterium and, when isolated, can be used as a basis for obtaining a biological vaccine, diagnostic and medicines.
- TB antigen species-specific glycoprotein tuberculosis complex
- the claimed invention is an agent having the property of forming cellular immunity against
- M. tubersulosis H37 Rv The product contains a species-specific glycoprotein tuberculosis complex M. tubersulosis H37 Rv (TB antigen).
- variants of the methods for producing the species-specific glycoprotein tuberculosis complex M. tubersulosis H37 Rv (TB antigen), as well as the recombinant strain 2-9XL Acipetobacterium HCP-VKPM-9312, the producer of the species-specific glycoprotein-complex M. tuberculosis 37 M. tuberculosis complex (M. tuberculosis), are claimed. ) and a tool for the diagnosis of tuberculosis containing the above species-specific glycoprotein tuberculosis complex.
- 2-9XL Asipetobaster johpsopii is a genetically engineered strain obtained by transferring two fragments of chromosomal DNA of M. tubulissis H37 Rv into the R plasmid P. tularepsis in the vector plasmid pRT and subsequent selection using a microbiological method.
- strain 2-9XL Acipetobaster joppsopii The main properties of strain 2-9XL Acipetobaster joppsopii - super producer of recombinant tuberculosis antigen.
- Cultural and morphological properties Under light microscopy ( Figures 1, 2 of the drawings. Light microscopy, bacteria 2-9XL Acipetobaster johpsopii. Gram stain (Set of dyes of the company "Serva"). Culture 2-9XL Acipetobacterium cultivated on a cultivated medium agar with 1% glucose and additives, pH 6.6) for three days at +32 0 C. A-Uv. 100X3 ...;
- the bacterial capsule is stained with red safranin) bacteria are immobile polymorphic small cocciform and rod-shaped cells 0.4-1.0 microns in size. When stained according to Gram, bacteria are resistant to discoloration, which gives the impression of gram-positive staining.
- Strain 2-9XL aerob grows on simple and rich media (auxotroph) at + 32 0 C, but can grow in the range from + 28 0 C to + 37 0 C.
- a necessary growth factor of 2-9XL is cysteine.
- rich media with vitamin and other additives are preferred.
- bacteria 2-9XL form gray-white colonies with a yellowish tint.
- growth retardation of up to two days is possible.
- the size of the colonies can be a SUBSTITUTE SHEET (RULE 26) reach a diameter of 5-7 mm. If the cups with sowing are kept for 2-3 days in the refrigerator (+4 0 C), 3 colonies acquire a predominantly yellow-gray color.
- the colonies are convex with uneven edges, not shiny, opaque, when taking a loop, the consistency of the colonies is dense, easily removed from the surface of nutrient agar.
- strain 2-9XL With successive transfers in dense nutrient media, cultivation at various temperature conditions, after storage in a freeze-dried state, deterioration of the nutritional properties of the growth medium and other adverse conditions, strain 2-9XL becomes unstable and dissociates into other forms. Dissociation is most noticeable after prolonged cultivation of isolated colonies ( Figures 6 to 11 of the drawings). Dissociation of culture 2-9XL Acipetobaster johpsopii according to cultural and morphological characteristics.
- SUBSTITUTE SHEET (RULE 26) Petri dish with dissociated culture 2-9XL. Colony growth of various morphologies during titration of culture from a lyophilized state. FT agar with 1% glucose, cysteine, pH 6.6. Incubation time at + 32 0 C for 10 days, storage in the refrigerator (+ 4 0 C).
- Figure 6 Petri dish photographed on a white background
- figure 7 Petri dish photographed on a gray background.
- Figures 8-11 Enlarged fragments of a Petri dish with colonies 2-9XL of different morphology.
- Figure 8 (1) Large round white opaque flat with a convex center and a smooth edge shiny colony, can be easily removed from the agar loop;
- Figure 8 (2) - Small round gray-yellow opaque convex with a smooth edge non-shiny colony, easily removed by loop from agar;
- Figure 9 The average round gray-yellow-white opaque with a convex well-defined center and a pronounced roller along a smooth edge is not a shiny colony, easily removed by loop from agar;
- Figure 10 Medium non-round yellow opaque with a pronounced convex center uneven surface and non-shiny colony edge, easily removed by loop from agar;
- Figure 11 Large, not round, yellow-gray opaque with a pronounced convex center, uneven surface and not brilliant colony with the edge, easily removed by loop from agar).
- Biochemical properties of strain 2-9XL Bacteria, when grown on solid nutrient media, break down proteins with a specific, non-irritating odor. When grown on rich nutrient media, they are able to synthesize a recombinant SUBSTITUTE SHEET (RULE 26) tuberculosis antigen. Oxide-positive and catalase-negative. The biochemical properties of the recombinant strain 2–9XL Acipetobacter joppsopii have not been fully studied.
- Bacteria 2-9XL have very high adhesion (the ability to stick) (See figures 1, 2 of the drawings), which does not allow to verify their agglutinability in the agglutination reaction.
- the TB antigen in the ultrasonic disintegrates of bacteria and in purified form interacts with the antibodies of the blood serum of people with tuberculosis and does not interact with antibodies in the blood serum of healthy people.
- the TB antigen does not interact with the antibodies of patients with tuberculosis, since it is not transferred to the nitrocellulose membrane.
- strain 2-9XL Asipetobacter johpsopii as part of the chromosomal DNA contains at least one insertion of a fragment of the chromosomal DNA M. tubersulosis H37 Rv, but two inserts are possible.
- Productivity Recombinant strain 2-9XL is a producer of a glycoprotein-derived tuberculosis antigen (TB antigen). Proteins synthesized from a fragment of the chromosomal DNA of M. tubersulosis H37 Rv form a species-specific glycoprotein complex on the outer membrane of the bacterium 2-9XL and in its capsule substance ( Figures 12-14 / drawings).
- Guinea pigs were immunized subcutaneously in the back to the scapular region with a TB antigen at a dose of 300 ⁇ g / ml with incomplete Freund's adjuvant. Three weeks later, the administration of the drug was repeated.
- the antibody response in laboratory animals was evaluated 21 days after the last administration of the TB antigen. For this, blood sampling was carried out, serum was obtained and the presence of specific TB antibodies in the diffuse precipitation reaction and by the enzyme immunoassay was checked.
- the presence of a recombinant TB antigen in animals causes a B-type rearrangement of their immune system.
- the prolonged presence of the TB antigen or its repeated administration makes the restructuring of the immune system persistent, as indicated by an increase in titers of specific antibodies in the blood serum of animals.
- SUBSTITUTE SHEET (RULE 26) In patients with tuberculosis of people and bacteria carriers, specific B-cell immunity is determined using TB antigen in enzyme-linked immunosorbent assays (ELISA), on nitrocellulose filters (Immunoblotting, Dot blot) and in other reactions using clinical fluids (blood serum, sputum, pleural fluid, cerebrospinal fluid and others) containing specific antibodies.
- ELISA enzyme-linked immunosorbent assays
- Dot blot enzyme-linked immunosorbent assays
- clinical fluids blood serum, sputum, pleural fluid, cerebrospinal fluid and others
- Serum samples are provided by gos. Research Institute for Standardization and Control of Medical and Biological Preparations L.A. Tarasevich (GISK) and LLC "BIOHOM". 460 people were examined.
- OP> 0.6 - indicates the presence of antibodies in the blood serum to the causative agent of tuberculosis; 0.3> OP ⁇ 0.6 - doubtful result ("gray zone");
- OP ⁇ 0.3 - indicates the absence of antibodies to the causative agent of tuberculosis;
- MBT + - the diagnosis of tuberculosis is confirmed by the release of mycobacteria from the patient;
- MBT- - the diagnosis of tuberculosis is confirmed by clinical and radiological methods.
- HIV - human immunodeficiency virus HBV - hepatitis B virus
- HCV - hepatitis C virus HCV - hepatitis C virus.
- Comparison drug REPLACEMENT SHEET served dry purified tuberculin (Tuberculum Derumatum sissum) produced by RAO "BIOPREPARAT", St.
- the TV antigen is very promising as a diagnostic drug for determining the presence of specific T-cell immunity in patients and people infected with tuberculosis and as a biological vaccine.
- LD 5O value for linear Balb / c mice and Golden hamsters exceeds IxIO 7 microbial cells and 5x10 7 microbial cells, respectively.
- Strain 2-9XL Asipetobaster johpsopii is avirulent for guinea pigs and rabbits (LD 5 value ( ⁇ IxIO 9 microbial cells per animal).
- strain 2–9XL Acipetobacter joppsopii can be assigned to the 4th group of microorganisms according to the International Classification.
- the conditions and composition of the media for storage and maintenance of the strain The museum culture of strain 2-9XL Acipetobaster is stored at a temperature of +4 0 C on the jambs of the FT medium with the addition of glucose and cysteine for up to 2 months, and in the lyophilized state in sucrose-gelatinous medium for up to 5 years.
- the recombinant strain 2-9XL Acipetobaster joppsopii is cultivated on a dense FT-medium with the addition of glucose and cysteine at + 32 0 C.
- the recombinant strain 2-9XL grows poorly in liquid culture media and quickly loses the ability to produce TB antigen. Therefore, the biomass build-up for the subsequent isolation of the TB antigen is carried out only on solid nutrient media.
- the matrix culture is grown on the jambs at + 32 0 C for 2-3 days, then the bacteria are washed off with physiological saline and one or two mattresses are sown from one pigtail.
- Mattresses SUBSTITUTE SHEET (RULE 26) incubated in a thermostat at + 32 0 C for 3-4 hours, then the grown biological mass is washed off with distilled water and centrifuged to remove soluble components of the nutrient medium. Recombinant TB antigen is released from the biological mass purified from the components of the nutrient medium.
- Example 1 Obtaining a species-specific glycoprotein tuberculosis complex (TB antigen) from a recombinant strain 2-9XL Acipetobacter j ohpsopii.
- pH 6.6 consisting of cardiac cerebral agar, hydrolyzed hemoglobin, cysteine and glucose in appropriate proportions or FT-agar pH 6.6 (Production of FSUE SSC PM, Obolensk, Russia) with the addition of cysteine and glucose loops make culture 2-9XL. Inoculation is incubated in an incubator at + 32 0 C for two days. The two-day culture is washed off with physiological saline and a suspension of bacteria is prepared at a concentration of 5x10 9 microbial cells (m.k.) in one milliliter.
- the bacterial population of the recombinant strain 2-9XL with small changes in the composition of the SUBSTITUTE SHEET (RULE 26) nutrient medium, temperature, or other conditions can quickly dissociate into forms that do not produce TB antigen. When stained according to Gram, these bacteria are gram-negative, bacteria producing TB antigen are resistant to discoloration and look like gram-positive (figures 1, 2 of the drawings). In the grown biomass 2-9XL, the number of gram-negative bacteria should not exceed 5-10%].
- the suspension of bacteria washed off the mattress is centrifuged ("Weightkmap" G2-21, USA) at 9000 rpm for 30 minutes.
- the supernatant containing soluble components of the nutrient medium is discarded, and the precipitate is suspended in 40 ml of chilled deionized water, and all subsequent procedures are done at + 4 ° C.
- the culture is treated with 2-9XL 0.5N NaOH solution, bringing the pH to 6, 0 to 9.0
- the dissolution of the capsule of bacteria that contains the species-specific recombinant TB antigen is carried out fractionally, adding NaOH in small portions and thoroughly mixing the suspension for several hours.
- the bacterial suspension thus treated is left in the refrigerator (+4 0 C) overnight (15-16 hours).
- the obtained first portion of the preparation of capsules 2-9XL in the cold is neutralized with a 0.5N trichloroacetic acid (TCA) solution to pH 6.0 and, since it contains a sufficiently large number of bacteria, it is centrifuged at 15000 rpm for a SUBSTITUTE SHEET (RULE 26) 40 minutes. The sediment is discarded and the supernatant acidified
- TCA 0.5N TCA to pH 3.0-3.5.
- the TB antigen is collected in the complex and begins to precipitate.
- the drug is left in the refrigerator (+4 0 C) at night (15-16 hours).
- the TCA precipitate deposited overnight in this solution can be stored at + 4 ° C for up to two weeks without losing the specific activity of the TB antigen present in it.
- a second portion of the drug is left in the refrigerator to form a TB antigen precipitate.
- the precipitate is dissolved in 1-2 ml of PBS buffer (0.0067M KH 2 PO 4 , 0.0067M Na 2 HPO 4 , 0 ⁇ 38M NaCl, 0.0027M KCl pH 7.0).
- PBS buffer solution contains predominantly species-specific TB antigen ( Figure 12 of the drawings. Electrophoresis of the TB antigen of the recombinant strain 2-9XL Acipetobaster jophsopii. 16% SDS-PAAG protein electrophoresis of the recombinant strain 2-9XL. 60-17 Ov. 60. glycine buffer pH 8.3.
- M - markers 67.0 kDa; 45.0 kDa; 25.0 Sha; 17.0 kDa; 12.3 kDa.
- the arrow indicates the double protein of the TB antigen, which does not exhibit specific activity;
- TCA trichloroacetic acid
- the arrow indicates the TB antigen in the assembly. This protein complex exhibits specific activity.), which already exhibits specific activity, but requires additional purification).
- the TCA precipitate that has fallen overnight can be stored at +4 0 C for up to two weeks without losing the specific activity of the TB antigen present in it.
- the next day a second portion of the drug is dissolved in 1-2 ml of PBS buffer. It contains predominantly species-specific TB antigen.
- the TB antigens of the first and second portions are combined and subjected to further purification.
- Example is the most economical production of TB antigen from the recombinant strain 2-9XL Acipetobaster joppsopii, but it does not exclude the possibility of obtaining it in any other way (Destruction of bacteria using ultrasound or by freezing-thawing, or otherwise , followed by the concentration of TB antigen).
- SUBSTITUTE SHEET (RULE 26) Example 2. Obtaining a species-specific glycoprotein tuberculosis complex (TB antigen) from the recombinant strain 2-9XL Asipetobaster steroid.
- a dense nutrient medium (kosyachki) with a pH of 6.6, consisting of cardiac cerebral agar, hydrolyzed hemoglobin, cysteine and glucose in appropriate proportions or FT agar pH 6.6 (Production of FSUE SSC PM, Obolensk, Russia) make inoculation loop culture 2-9XL. Inoculation is incubated in an incubator at + 32 0 C for three days. A three-day culture is washed off with physiological saline and a suspension of bacteria is prepared at a concentration of 5x10 9 microbial cells (m.k.) in one milliliter.
- microbial cells m.k.
- the resulting suspension is sown on mattresses at the rate of one joint for 1-2 mattresses (400.0 ml of culture medium is poured into one mattress). Inoculation is incubated in an incubator at + 32 0 C for three days. From one mattress, a three-day culture of 2-9XL is washed off with 30 ml of physiological saline. A smear for light microscopy is prepared from the suspension of the washed culture and stained with Gram (Monitoring for the presence of TB antigen in recombinant bacteria 2-9XL). The suspension of bacteria washed off the mattress is centrifuged
- the 2-9XL bacterial suspension was centrifuged at 12,000 rpm for 40 minutes.
- the supernatant partially dissolved capsule of the recombinant strain 2-9XL 3 containing the TB antigen
- the precipitate bacteria 2-9XL, which have preserved and not preserved the capsule.
- To the precipitate add 40 ml of deionized water and repeat the procedure for dissolving the capsule, obtaining a second portion of the drug.
- the second portion of the preparation is neutralized with a 0.5N trichloroacetic acid solution (TCA) to a pH of 6.0, and then ammonium sulfate [(NSCHSOJ up to 30% saturation, added overnight at +4 0 C to precipitate.
- TCA 0.5N trichloroacetic acid solution
- ammonium sulfate [(NSCHSOJ up to 30% saturation, added overnight at +4 0 C to precipitate.
- the next the preparation of TB antigen precipitated during 100% precipitation with ammonium sulfate is centrifuged at 12,000 rpm for 40 minutes, the supernatant is discarded, the precipitate is dissolved in 2.0 ml of PBS buffer, pH 7.0 (based on one mattress ) and dialyzed against a large volume of PBS buffer.
- SUBSTITUTE SHEET (RULE 26) During the day, the volumes of the PBS buffer are changed at least three times to completely remove ammonium sulfate from the
- the second portion of the preparation containing 30% ammonium sulfate is centrifuged at 12,000 rpm for 40 minutes and the precipitate is discarded, the supernatant is saturated with 100% ammonium sulfate and left overnight at +4 0 C.
- M markers 67.0 kDa; 45.0 kDa; 25.0 kDa; 17.0 kDa; 12.3 kDa.
- the TB antigens of the first and second portions are combined and subjected to further purification.
- a species-specific glycoprotein tuberculosis complex SUBSTITUTE SHEET (RULE 26) (TB antigen) from the recombinant strain 2-9XL is possible not only by precipitation of it from alkaline lysates with trichloroacetic acid to a pH of 3.5-4.0, as shown in Example 1. It is possible to use methods of precipitation of TB antigen using various salts for example, ammonium sulfate or other methods, eluates contain purified TB antigen with a molecular weight of 55.0 to 75.0 kDa and the presence of carbohydrates from 20% to 50%.
- Example 3 Purification of a species-specific glycoprotein tuberculosis complex (TB antigen) obtained from the recombinant strain 2-9XL Acipetobaster ojpsopii.
- the total carbohydrate content is determined by the phenolic method 151.
- the eluates contain purified TB antigen with a molecular weight of 55.0 to 75.0 kDa and the presence of carbohydrates from 20% to 50%.
- Specific tuberculous recombinant antigens are stored at +4 0 C in freeze-dried condition.
- SUBSTITUTE SHEET (RULE 26) The presence of purified TB antigen and its structure obtained by the above method are recorded in SDS-PAAG electrophoresis gel ( Figure 14 of the drawings. Electrophoresis of TB antigen of recombinant strain 2-9XL Acipetobacter johnsopii. 17% SDS-PAAG complex of recombinant 2 recombinant electrophoresis 9XL by Lamley 60-17 Ov 60 minutes Tris-glycine buffer pH 8.3.
- M - markers 67.0 kDa; 45.0 kDa; 25.0 kDa; 17.0 kDa; 12.3 kDa.
- the vertical arrows indicate the TB antigen in the assembly. This protein complex exhibits specific activity.
- the side arrows indicate the components of the protein complex).
- Obtaining purified TB antigen is possible not only by fractionation of macromolecules by gel filtration using various carriers as a matrix, but also by ion exchange chromatography.
- Example 4 The use of purified species-specific TB antigen in the diagnosis of human tuberculosis.
- test system which is an indirect enzyme-linked immunosorbent assay with phase separation, where 96-well plates are used as a solid support.
- the substrate for ELISA is a tuberculosis antigen obtained from recombinant strain 2-9X by chromatographic fractionation.
- SUBSTITUTE SHEET (RULE 26) 100 ⁇ l of antigen in concentration are added to the wells of the plate.
- reaction mixture was incubated for 1 hour at 37 ° C, after which the cells were washed five times with PBS-Twep 20.
- a substrate solution was prepared by adding 3 ⁇ l of 30% H 2 O 2 to 10 ml of freshly prepared
- the plate is incubated at +37 ° C for one hour, 100 ⁇ l of 1% SDS are added to stop the enzymatic reaction, and the light absorption at 405 nm is measured on a Bio-Rad vertical model 680 photometer. The results are compared with a vertical well blank series in which there was serum that did not contain specific antibodies.
- the purified recombinant TB antigen interacts only with the blood serum antibodies of people with tuberculosis and does not interact with the blood serum antibodies of healthy people.
- the recombinant 2-9XL TB antigen can be used for diagnostic purposes on a solid phase carrier, nitrocellulose membrane and other test systems that identify specific antibodies that are produced by the human body for the presence or propagation of the M. tuberculosis pathogen in it. tubersulosis H37 Rv.
- Specific antibodies produced by humans in response to the penetration and development of the causative agent of tuberculosis in them can be found not only in blood serum, but also in other clinical fluids (sputum, exudate, urine, and so on).
- Monoclonal antibodies or hyperimmune sera of various animals obtained on purified recombinant TB antigen can be used in diagnostic methods when searching in human clinical fluids (sputum, exudate, material
- SUBSTITUTE SHEET (RULE 26) microbiopsies and so on) both mycobacterium tuberculosis and their specific components.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880024159A CN101861166A (zh) | 2007-05-10 | 2008-04-29 | 展示形成对抗结核分枝杆菌H37 Rv的细胞免疫性质的制剂、其(变体)制备方法、重组菌株及用于结核病诊断的制剂 |
EP08767027A EP2156844A4 (en) | 2007-05-10 | 2008-04-29 | PRODUCT CAPABLE OF FORMING CELLULAR IMMUNITY AGAINST MYCOBACTERIUM TUBERCULOSIS H37 RV, MANUFACTURING METHOD THEREOF (AND VARIANTS), RECOMBINANT STRAIN AND PRODUCT FOR DIAGNOSING TUBERCULOSIS |
EA200901503A EA014065B1 (ru) | 2007-05-10 | 2008-04-29 | Средство, обладающее свойством формировать клеточный иммунитет против mycobacterium tuberculosis h37 rv, способ получения его (варианты), рекомбинантный штамм и средство для диагностики туберкулеза |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007117342 | 2007-05-10 | ||
RU2007117342/13A RU2341288C1 (ru) | 2007-05-10 | 2007-05-10 | СРЕДСТВО, ОБЛАДАЮЩЕЕ СВОЙСТВОМ ФОРМИРОВАТЬ КЛЕТОЧНЫЙ ИММУНИТЕТ ПРОТИВ MYCOBACTERIUM TUBERCULOSIS H37 Rv, СПОСОБ ПОЛУЧЕНИЯ ЕГО (ВАРИАНТЫ), РЕКОМБИНАНТНЫЙ ШТАММ И СРЕДСТВО ДЛЯ ДИАГНОСТИКИ ТУБЕРКУЛЕЗА |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008140353A1 true WO2008140353A1 (ru) | 2008-11-20 |
WO2008140353A8 WO2008140353A8 (ru) | 2009-07-16 |
Family
ID=40002430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2008/000270 WO2008140353A1 (ru) | 2007-05-10 | 2008-04-29 | Средство, обладающее свойством формировать клеточный иммунитет против мусоbасtеrium tubеrсulоsis h37 rv, способ получения его (варианты), рекомбинантный штамм и средство для диагностики туберкулеза |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2156844A4 (ru) |
CN (1) | CN101861166A (ru) |
EA (1) | EA014065B1 (ru) |
RU (1) | RU2341288C1 (ru) |
UA (1) | UA96488C2 (ru) |
WO (1) | WO2008140353A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101603017B (zh) * | 2009-06-05 | 2012-07-04 | 天津科技大学 | 一种约氏不动杆菌lp28以及利用该菌制备低温碱性脂肪酶的方法 |
CN103675293B (zh) * | 2013-11-25 | 2015-10-28 | 广东体必康生物科技有限公司 | Rv3872、Rv0164和/或Rv1926c蛋白在制备诊断活动性肺结核的产品中的用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB860305A (en) * | 1958-06-12 | 1961-02-01 | Yamamura Yuichi | Tuberculin active peptide |
RU2237090C1 (ru) * | 2003-04-24 | 2004-09-27 | Институт химической биологии и фундаментальной медицины СО РАН | Способ генетического типирования штаммов микобактерий туберкулезного комплекса |
RU2262351C1 (ru) * | 2003-12-26 | 2005-10-20 | ООО "Фирма "БиоМедИнвест" | Вакцинная композиция для профилактики и лечения туберкулезной инфекции и генетические конструкции для получения действующих компонентов этой композиции |
US7112663B1 (en) * | 1998-04-16 | 2006-09-26 | Institut Pasteur | Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library, application to the detection of mycobacteria |
CN1869239A (zh) * | 2006-06-01 | 2006-11-29 | 南京农业大学 | 一种融合蛋白的酵母表达载体及其基因工程产品 |
-
2007
- 2007-05-10 RU RU2007117342/13A patent/RU2341288C1/ru not_active IP Right Cessation
-
2008
- 2008-04-29 WO PCT/RU2008/000270 patent/WO2008140353A1/ru active Application Filing
- 2008-04-29 CN CN200880024159A patent/CN101861166A/zh active Pending
- 2008-04-29 EP EP08767027A patent/EP2156844A4/en not_active Withdrawn
- 2008-04-29 EA EA200901503A patent/EA014065B1/ru not_active IP Right Cessation
- 2008-04-29 UA UAA200912563A patent/UA96488C2/ru unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB860305A (en) * | 1958-06-12 | 1961-02-01 | Yamamura Yuichi | Tuberculin active peptide |
US7112663B1 (en) * | 1998-04-16 | 2006-09-26 | Institut Pasteur | Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library, application to the detection of mycobacteria |
RU2237090C1 (ru) * | 2003-04-24 | 2004-09-27 | Институт химической биологии и фундаментальной медицины СО РАН | Способ генетического типирования штаммов микобактерий туберкулезного комплекса |
RU2262351C1 (ru) * | 2003-12-26 | 2005-10-20 | ООО "Фирма "БиоМедИнвест" | Вакцинная композиция для профилактики и лечения туберкулезной инфекции и генетические конструкции для получения действующих компонентов этой композиции |
CN1869239A (zh) * | 2006-06-01 | 2006-11-29 | 南京农业大学 | 一种融合蛋白的酵母表达载体及其基因工程产品 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2156844A4 * |
Also Published As
Publication number | Publication date |
---|---|
RU2341288C1 (ru) | 2008-12-20 |
UA96488C2 (ru) | 2011-11-10 |
CN101861166A (zh) | 2010-10-13 |
EA200901503A1 (ru) | 2010-04-30 |
WO2008140353A8 (ru) | 2009-07-16 |
EP2156844A4 (en) | 2010-12-29 |
EA014065B1 (ru) | 2010-08-30 |
EP2156844A1 (en) | 2010-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102836425B (zh) | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 | |
KR100331358B1 (ko) | 그룹B스트렙토코커스의많은균주들에대한면역성을제공하는세포표면단백질인Rib단백질,그단백질의정제방법,시약키트및제약조성물 | |
Thomas et al. | Studies on primary atypical pneumonia. II. Observations concerning the relationship of a non-hemolytic streptococcus to the disease | |
CN102238960B (zh) | 制造疫苗的方法 | |
CN109182167B (zh) | 一种高效价结核菌素皮试诊断试剂(ppd)生产工艺 | |
AU2005288678A1 (en) | Immunogenic glycopeptides for diagnosing pathogenic microorganisms infections | |
KR100951057B1 (ko) | 면역특이단백질 항원을 사용하는 우결핵 특이 효소면역진단키트 및 이를 이용한 우결핵 진단방법 | |
US3636192A (en) | Meningococcal polysaccharide vaccines | |
Shinoda et al. | Inhibitory effect of capsular antigen of Vibrio vulnificus on bactericidal activity of human serum | |
RU2341288C1 (ru) | СРЕДСТВО, ОБЛАДАЮЩЕЕ СВОЙСТВОМ ФОРМИРОВАТЬ КЛЕТОЧНЫЙ ИММУНИТЕТ ПРОТИВ MYCOBACTERIUM TUBERCULOSIS H37 Rv, СПОСОБ ПОЛУЧЕНИЯ ЕГО (ВАРИАНТЫ), РЕКОМБИНАНТНЫЙ ШТАММ И СРЕДСТВО ДЛЯ ДИАГНОСТИКИ ТУБЕРКУЛЕЗА | |
TW403655B (en) | Novel attenuated pseudomonas aeruginosa strains | |
CN101248084B (zh) | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 | |
KR100968069B1 (ko) | 우결핵균 특이단백질 및 그 정제방법 | |
Saunders et al. | Immunoblot analysis of antigens associated with Haemophilus ducreyi using serum from immunised rabbits. | |
HUT77574A (hu) | Eljárás fokozott antigénaktivitású Helicobacter sp. és azt tartalmazó vakcina előállítására | |
US8663940B2 (en) | Ex-vivo passive protection bacteremia assay | |
RU2627897C1 (ru) | Способ получения антигена для определения противобруцеллезного иммунитета | |
HUT77876A (hu) | Eljárás fokozott antigénaktivitású bélbaktériumok és azokat tartalmazó vakcinák előállítására | |
AU2003213233A1 (en) | Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections | |
Vasconcellos et al. | Vaccine Against Entheropathogenic E. coli: A Systematic Review | |
Cooper et al. | Immunogenicity of ribosomal preparations from Neisseria gonorrhoeae | |
Nyirenda | Natural immunity to Salmonella in humans | |
Widen et al. | Agar microdroplet assay for delayed hypersensitivity to Legionella pneumophila serogroup 1 | |
Baron et al. | Genetic transformation of pilation and virulence into Neisseria gonorrhoeae T4 | |
Saunders et al. | Humoral response of the mouse to Treponema pallidum. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880024159.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08767027 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6574/CHENP/2009 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200901503 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008767027 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: a200912563 Country of ref document: UA |